30 September 2026
CVS Group plc
("CVS" or the "Company")
Total Voting Rights & Confirmation of Dividend Dates
CVS, the UK listed veterinary group and a leading provider of veterinary services, announces that, as of 30 September 2026, following cancellation of the Ordinary Shares purchased pursuant to the Company's share buyback programme (announced on 26 May 2026) prior to the date of this announcement, the Company's total issued share capital consists of 67,460,830 ordinary shares of 0.2p each ("Ordinary Shares").
This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.
Confirmation of Dividend Dates
Following the announcement of the Company’s Final Results for the year ended 30 June 2026 on 24 September 2026, the Company confirms the correct dates for the final dividend as follows:
|
Contacts: |
|
|
CVS Group plc |
via FGS Global |
|
Scott Morrison, Group General Counsel and Company Secretary
|
|
|
FGS Global |
|
|
Faeth Birch |
+44 (0)207 251 3801 |
|
Charlie Chichester |
cvsgroup@fgsglobal.com |
About CVS Group plc (www.cvsukltd.co.uk)
CVS Group is a leading provider of veterinary services, operating in the UK and Australia, listed on the Main Market of the London Stock Exchange. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.
The Group operates over 475 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").
The Group employs 9,000 personnel, including 2,500 veterinary surgeons and 3,300 nurses.